The ability of MsEO to inhibit AChE suggests a promising potential for modulating acetylcholine levels, which could contribute to improving cognitive symptoms associated with Alzheimer’s disease [63]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.